• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Events per person year--a dubious concept.每人每年发生的事件——一个可疑的概念。
BMJ. 1995 Feb 18;310(6977):454-6. doi: 10.1136/bmj.310.6977.454.
2
The ethics of placebo in studies with fracture end points in osteoporosis.骨质疏松症骨折终点研究中安慰剂的伦理学问题
N Engl J Med. 2010 Sep 30;363(14):1367-70; discussion e21. doi: 10.1056/NEJMsb1006120.
3
Risedronate for the prevention and treatment of postmenopausal osteoporosis.利塞膦酸盐用于预防和治疗绝经后骨质疏松症。
Cochrane Database Syst Rev. 2003(4):CD004523. doi: 10.1002/14651858.CD004523.
4
The treatment of osteoporosis. Antiresorptive therapy.骨质疏松症的治疗。抗吸收治疗。
Clin Lab Med. 2000 Sep;20(3):603-22, viii.
5
Risedronate for the prevention of fractures in postmenopausal osteoporosis.
Ann Pharmacother. 2002 Apr;36(4):664-70. doi: 10.1345/aph.1A221.
6
Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.绝经后骨质疏松症的抗吸收治疗:随机临床研究综述及依维斯他(阿仑膦酸盐)对比(EVA)试验的理论依据
Curr Med Res Opin. 2004 Mar;20(3):351-7. doi: 10.1185/030079904125003071.
7
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.阿仑膦酸钠用于绝经后妇女骨质疏松性骨折的一级和二级预防。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD001155. doi: 10.1002/14651858.CD001155.pub2.
8
Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.绝经后骨质疏松症的抗吸收治疗:以骨折为终点的大型临床试验中研究设计与结果的比较
Endocr Rev. 2002 Feb;23(1):16-37. doi: 10.1210/edrv.23.1.0453.
9
Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.阿仑膦酸钠用于治疗骨质疏松症。安全有效的非激素疗法。
Can Fam Physician. 1998 Feb;44:327-32.
10
Surrogates for fracture endpoints in clinical trials.临床试验中骨折终点的替代指标。
J Bone Miner Res. 2003 Jun;18(6):1146-9. doi: 10.1359/jbmr.2003.18.6.1146.

引用本文的文献

1
The GLP-1 receptor is expressed by human metastatic prostate cancer.人转移性前列腺癌表达胰高血糖素样肽-1受体。
Endocr Oncol. 2024 Jan 22;4(1):e230015. doi: 10.1530/EO-23-0015. eCollection 2024 Jan 1.
2
Adult Attention-Deficit/Hyperactivity Disorder and the Risk of Dementia.成人注意缺陷多动障碍与痴呆风险。
JAMA Netw Open. 2023 Oct 2;6(10):e2338088. doi: 10.1001/jamanetworkopen.2023.38088.
3
Continuous Glucose Monitoring: Impact on Hypoglycemia.持续血糖监测:对低血糖的影响
J Diabetes Sci Technol. 2016 Nov 1;10(6):1251-1258. doi: 10.1177/1932296816653411. Print 2016 Nov.
4
IQWiG Reanalyzes and Raises Questions About an Article by Ly et al Which Concluded Low Glucose Suspend Is Very Beneficial.德国卫生经济与健康技术评估研究所(IQWiG)重新分析了Ly等人的一篇文章,并对其提出质疑,该文章得出低葡萄糖暂停非常有益的结论。
J Diabetes Sci Technol. 2015 Aug 6;10(1):185-90. doi: 10.1177/1932296815597918.
5
Incidence rates in dynamic populations.动态人群中的发病率。
Int J Epidemiol. 2012 Oct;41(5):1472-9. doi: 10.1093/ije/dys142.
6
Evaluation of benefit-risk.效益风险评估。
Pharmacoeconomics. 2010;28(11):981-6. doi: 10.2165/11537590-000000000-00000.
7
On reporting results from randomized controlled trials with recurrent events.关于报告复发性事件的随机对照试验结果
BMC Med Res Methodol. 2008 May 30;8:35. doi: 10.1186/1471-2288-8-35.
8
Wounds in advanced illness: a prevalence and incidence study based on a prospective case series.晚期疾病中的伤口:一项基于前瞻性病例系列的患病率和发病率研究。
Int Wound J. 2008 Jun;5(2):305-14. doi: 10.1111/j.1742-481X.2007.00379.x.
9
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors.关于在环氧化酶-2和肿瘤坏死因子α抑制剂随机对照试验中报告不良反应时纳入时间因素的调查。
Ann Rheum Dis. 2007 Jan;66(1):124-7. doi: 10.1136/ard.2006.055848. Epub 2006 Jul 10.
10
Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.1型糖尿病成年患者中短效胰岛素类似物的荟萃分析:持续皮下胰岛素输注与注射治疗对比
Diabetologia. 2004 Nov;47(11):1895-905. doi: 10.1007/s00125-004-1545-x. Epub 2004 Nov 25.

本文引用的文献

1
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.氟化物/钙疗法对绝经后骨质疏松症患者椎体骨折发生率的影响。与传统疗法的比较。
N Engl J Med. 1982 Feb 25;306(8):446-50. doi: 10.1056/NEJM198202253060802.
2
Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis.196项类风湿性关节炎非甾体抗炎药双盲试验报告中的方法学以及显性和隐性偏差。
Control Clin Trials. 1989 Mar;10(1):31-56. doi: 10.1016/0197-2456(89)90017-2.
3
Effect of calcitonin and vitamin D in osteoporosis.降钙素和维生素D在骨质疏松症中的作用。
Calcif Tissue Int. 1989 Sep;45(3):137-41. doi: 10.1007/BF02556055.
4
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.氟化物治疗对绝经后骨质疏松症女性骨折率的影响。
N Engl J Med. 1990 Mar 22;322(12):802-9. doi: 10.1056/NEJM199003223221203.
5
T-cell receptors in ataxia-telangiectasia.共济失调毛细血管扩张症中的T细胞受体
N Engl J Med. 1990 Oct 25;323(17):1210-1. doi: 10.1056/NEJM199010253231714.
6
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.间歇性周期性依替膦酸治疗绝经后骨质疏松症。
N Engl J Med. 1990 Jul 12;323(2):73-9. doi: 10.1056/NEJM199007123230201.
7
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.间歇性周期性依替膦酸治疗对绝经后骨质疏松症女性骨量和骨折率的影响。
N Engl J Med. 1990 May 3;322(18):1265-71. doi: 10.1056/NEJM199005033221803.
8
Prevention of restenosis by lovastatin after successful coronary angioplasty.洛伐他汀预防冠状动脉血管成形术成功后再狭窄的研究
Am Heart J. 1991 Jun;121(6 Pt 1):1600-8. doi: 10.1016/0002-8703(91)90002-y.
9
A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis.
Osteoporos Int. 1991 Jun;1(3):155-61. doi: 10.1007/BF01625446.
10
Treatment of postmenopausal osteoporosis with calcitriol or calcium.
N Engl J Med. 1992 Feb 6;326(6):357-62. doi: 10.1056/NEJM199202063260601.

每人每年发生的事件——一个可疑的概念。

Events per person year--a dubious concept.

作者信息

Windeler J, Lange S

机构信息

Institut für Medizinische Biometrie, Ruprecht-Karls-Universität Heidelberg, Germany.

出版信息

BMJ. 1995 Feb 18;310(6977):454-6. doi: 10.1136/bmj.310.6977.454.

DOI:10.1136/bmj.310.6977.454
PMID:7873955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2548825/
Abstract

In 1982 a new measure was introduced in research into osteoporosis and is now used everywhere in the literature. The so called "fracture rate" relates the number of fractures (single in some patients, multiple in others) to the cumulative time of observation of all patients. This concept, however, has no sound basis. Counting events instead of patients usually violates basic statistical assumptions and invalidates the use of common statistical tests and estimators. Its clinical interpretation is rather dubious. The use of such a measure impedes the search for valid and clinically meaningful outcome criteria and should be abandoned.

摘要

1982年,骨质疏松症研究引入了一项新指标,如今该指标在文献中随处可见。所谓的“骨折率”是指骨折数量(有些患者为单发骨折,有些患者为多发骨折)与所有患者累计观察时间的比值。然而,这一概念并无可靠依据。统计事件而非患者通常会违反基本的统计假设,使常用统计检验和估计量的使用无效。其临床意义相当可疑。使用这样的指标会妨碍寻找有效且具有临床意义的结局标准,因此应该摒弃。